Clinical Research Directory
Browse clinical research sites, groups, and studies.
Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
Sponsor: Peking Union Medical College Hospital
Summary
This study has been designed as a 12-month, open-label randomized controlled clinical trial. The study aims to compare the efficacy and safety of two treatment strategies in IgG4-RD patients with superficial organ involvement: prednisone plus iguratimod and prednisone plus leflunomide.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2022-07-01
Completion Date
2026-04-30
Last Updated
2026-04-07
Healthy Volunteers
No
Conditions
Interventions
glucocorticoid plus iguratimod
Patients in Group I are treated with prednisone (≤20 mg qd, or equivalent glucocorticoid, taper to ≦ 5mg in 3 months) and iguratimod (25 mg bid).
glucocorticoid plus leflunomide
Patients in Group II are treated with prednisone (≤20 mg qd, or equivalent glucocorticoid, taper to ≦ 5mg in 3 months ) and leflunomide (10-20 mg qd).
Locations (1)
Peking Union Medical College Hospital
Beijing, China